申请人:Neurocrine Biosciences, Inc.
公开号:US05795905A1
公开(公告)日:1998-08-18
CRF receptor antagonists are disclosed. Such receptor antagonists are thiadiazole-, pyrimidine-, triazine-, and triazole-containing compounds substituted with both a C3-C14 monocyclic or fused, homoaryl or heteroaryl group and a substituted amine group. The CFR receptor antagonists have utility in the treatment of a variety of disorders, including disorders associated with the hypersecretion of CRF.
CRF受体拮抗剂已被披露。这些受体拮抗剂是噻二唑、嘧啶、三嗪和三唑含有化合物,其被取代的部分包括C3-C14的单环或融合、同源芳基或杂环基团和取代胺基团。CRF受体拮抗剂在治疗各种疾病中具有用途,包括与CRF过度分泌相关的疾病。